ArticleRheumatology (Oxford, England)2026
Radiomic analysis of high-resolution computed tomography predicts interstitial lung disease progression and mortality in systemic sclerosis.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe automated assessment of chest high-resolution CT (HRCT) scans allows the objective quantification of interstitial lung disease (ILD)-related features. Here, we explored the ability of HRCT-derived radiomic features to predict all-cause mortality and ILD progression in SSc-ILD patients.
methodsWe analysed baseline and follow-up HRCT scans of SSc-ILD patients using lung texture analysis (LTA™, Imbio). Lung parenchymal alterations (honeycombing, ground-glass, reticulation, hyperlucency) and pulmonary vessel volume (PVV) were quantified as percentages of the respective lung volume-for whole lungs and for upper, middle and lower zones. Univariable and multivariable Cox regression and generalized estimating equation (GEE) models were applied to identify radiomics predictors of all-cause mortality and ILD progression, respectively.
resultsOf 313 SSc-ILD patients, 267 (85%) were eligible for radiomic analysis and were included in the mortality analysis; 160 (60%) were included in the progression analysis. Over 42 [interquartile range (IQ)R 27-110] months of follow-up, 65 (24%) patients died. They presented with a greater extent of PVV% and parenchymal alterations across all lung zones, compared with patients who survived. PVV% independently predicted mortality [adjusted hazard ratio (HR) 1.21, 95% CI 1.094-1.354], particularly in the upper zones (adjusted HR 1.28, 95% CI 1.11-1.46). Among 261 yearly follow-up visits from 160 SSc-ILD patients, 50.6% showed at least one episode of ILD progression, for a total of 99 (37.7%) episodes. Baseline radiomic features were overall comparable between progressors and non-progressors. The extent of whole-lung honeycombing was identified as the only independent radiomic predictor of ILD progression [adjusted odds ratio 1.53, 95% CI 1.17-2.01].
conclusionThe PVV% and the extent of honeycombing independently predict mortality and ILD progression, respectively. These radiomic features might support risk stratification of SSc-ILD patients, on top of functional and clinical characteristics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.